Veracyte Stock Plunges 55%: A Small Guidance Cut Erased Half Its Value

Veracyte (NASDAQ: VCYT) stock plunged about 55% on Thursday, November 5, 2026 — falling from a previous close of $52.52 to around $23.69 — after the cancer diagnostics company trimmed its full-year 2026 testing revenue guidance, even though its third-quarter results beat expectations.

What happened?

Veracyte reported its third-quarter 2026 results on Wednesday, November 4, after the close. On the surface, the quarter looked solid. Total revenue rose 15% to $151.8 million, from $131.9 million a year earlier, and testing revenue also rose 15% to $146.4 million. The company was profitable, cash-generative, and ahead of Wall Street forecasts.

Then came the outlook. Veracyte lowered its full-year 2026 testing revenue guidance to $571 million to $573 million, down from $576 million to $582 million. Total revenue guidance moved to $590 million to $593 million, from $590 million to $596 million previously. It was, in dollar terms, a modest trim — a few million dollars off a range of nearly $580 million. In market terms, it erased more than half the company’s value in a single session.

Why did such a small cut cause such a huge fall?

The cut was not really about the dollars. It was about what it revealed. Management said Decipher Prostate test volume trailed expectations, while its Afirma thyroid test outperformed. For a diagnostics company priced for steady volume growth in a handful of key test franchises, weakness in one flagship product raises a bigger question: is the growth story slowing?

Chief Executive Marc Stapley described the quarter as solid, with strong profitability and cash generation. He noted Afirma beat its plan while Decipher Prostate volume fell short, and the company said its revised outlook includes only minimal revenue from recently launched tests. That caution helped explain why investors did not treat the trim as a one-off rounding change.

The reaction was amplified by an analyst downgrade. Leerink Partners lowered Veracyte to market perform from outperform on November 5, with a $35 price target, according to published coverage. When a guidance cut and a downgrade land on the same morning, in a market already punishing tech and growth names, selling can feed on itself.

The quarter underneath the crash

The reported numbers themselves did not collapse. GAAP net income was $31.5 million, or 20.8% of revenue. Diluted GAAP earnings were $0.38 per share, and non-GAAP diluted earnings were $0.51 per share — topping analysts’ consensus estimates of $0.41 by $0.10. Adjusted EBITDA was $41.2 million, or 27.2% of revenue, and operating cash flow was $40.3 million.

The balance sheet was not the problem either. Cash, cash equivalents and short-term investments stood at $370.5 million, and the board authorized up to $100 million of share repurchases over 12 months. The adjusted EBITDA margin outlook of more than 26% was left unchanged. This was a repricing of expectations, not a liquidity crisis.

Why it is blowing up

A fall of more than 50% is rare for a profitable company on a guidance change this small, and that rarity is exactly why the move dominated mover lists on Thursday. Finnhub market data showed the stock down more than 56% at one point, near $23.05, with an intraday low around $22.00 — well below its previous 52-week low of $29.45. Seeking Alpha reported shares fell more than 50% on Thursday after the outlook cut and the Leerink downgrade.

The move also fits the pattern of this earnings season. Again and again in recent days, stocks that beat on the quarter but guided even slightly lower have been punished far more than the guidance change alone would suggest. Veracyte is now the extreme example of that pattern: a 15% revenue increase and an earnings beat, followed by a halving of the share price.

What happens next?

The next test is fourth-quarter Decipher Prostate volume. If volumes recover, investors may conclude Thursday was an overreaction to a cautious outlook. If they stay soft, the lower guidance will look like the start of a slower growth path rather than a blip. Watchers will also look at how quickly Veracyte uses its $100 million buyback authorization, and whether recently launched tests begin to contribute more than the minimal revenue assumed in the revised outlook.

For now, the facts are simple: the quarter beat, guidance fell a little, and the stock fell a lot. That gap is why Veracyte was Thursday’s most dramatic mover.

Sources

Kalkine — Veracyte plunge and guidance details
Seeking Alpha — Veracyte downgraded at Leerink on guidance cut
Ticker Report — Veracyte beats EPS estimates by $0.10
Kraken — Veracyte stock price and day range

FAQ

Why did Veracyte stock fall about 55%?

Veracyte trimmed its 2026 testing revenue guidance to $571–$573 million from $576–$582 million after Decipher Prostate volumes trailed expectations, and Leerink downgraded the stock the same day.

Did Veracyte beat earnings in Q3 2026?

Yes. Non-GAAP earnings were $0.51 per share, beating consensus of $0.41, on revenue of $151.8 million, up 15% year over year.

What were Veracyte’s Q3 profit and cash figures?

GAAP net income was $31.5 million, adjusted EBITDA was $41.2 million, operating cash flow was $40.3 million, and liquidity stood at $370.5 million.

What should investors watch next?

Fourth-quarter Decipher Prostate volumes, uptake of recently launched tests, and use of the $100 million share repurchase authorization.